Imcyse, A Belgian Biotech To Start A Human Clinical Trial For Curing Type 1 Diabetes In Patients
Imcyse is a Belgian biotech company founded by Professor Jean-Marie Saint-Remy in July 2010. The treatment for type 1 diabetes is based on proprietary technology platform with the work done by its research study group based at the Catholic University of Leuven (KUL) (also known as the University of Leuven) Belgium.
The company is going to launch a Phase Ib trial for patients with type 1 diabetes (T1D) as the company has got approval from the British and Belgian regulatory authorities. The European Union through the EXALT program is funding the study.
The first trial on humans is going to be conducted at 18 clinical sites in Belgium, Denmark, Germany, France and the UK. Imcyse is going to collaborate with the French National Institute of Health and Medical Research (Inserm) in conducting the human trials.
The immunotherapy technology is intended to stop the death of beta cells in the pancreas (which produces insulin) in patients diagnosed with type 1 diabetes (T1D). The trial results are expected during 2018.
The existing therapies or treatments can either reduce the symptoms of type 1 diabetes (T1D) or slow the progress of type 1 diabetes (T1D). But the objective of the immunotherapy technology is to cure type 1 diabetes (T1D) in a patient.
The transplantation of beta cells, which is in the developmental stage is the other option for the treatment of type 1 diabetes (T1D) in a patient.
Heartisans Watch, A Wearable Smartwatch Device That Can Alert You Before A Heart Attack
Tim Lui Hin-wai, a biomedical engineer, aged 27 years, the co-founder of Heartisans, a Hong Kong-based technology start-up company. He developed a mobile App and a Smartwatch, a wearable technology device which can predict a heart attack ten minutes before it is going to happen. This device was developed specifically for a high-risk patient with heart disease and hypertension (high blood pressure. BP ).
The Smartwatch is containing an electrocardiogram (ECG) sensor which can read the electrical activity of the heart and can pass the information to a mobile App. The smartphone App analyzes the real-time changes and alerts the user ten minutes before the imminent heart attack (or coronary artery disease). The following are the features of the wearable Smartwatch device.
The wearable Smartwatch is in the testing process at the Queen Mary Hospital, Hong Kong on those patients who experienced a heart attack (and likely to have another heart attack) and also on patients with high risk of heart attack. Knowing the heart attack ten minutes before it is going to happen can save the life of a patient.
Tim Lui Hin-wai is planning 2-year long trial with the new mobile App and Smartwatch to check congestive heart failure on 600 patients of heart diseases. They are planning to monitor the development of congestive heart failure and the effects of the treatments on the heart.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.